Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 66 references it cites were found in a registry or an index; 56 of the 83 sources its claims cite were checked for support.

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

Open access

Abstract

Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.

Overview

CoChat Summary

TL;DR

This multicenter diagnostic study evaluated five plasma biomarkers in 6,896 cognitively impaired individuals and estimated how positive and negative predictive values change with age, syndrome, and APOE ε4 status. Plasma p-tau217 performed best: it could rule in amyloid-β pathology in probable AD dementia and older MCI, and rule it out in most non-AD dementia syndromes.

Key findings

  • In MCI, plasma p-tau217 PPV rose with age, reaching 80.9% at age 65 and 92.5% at age 90; its NPV fell with age, from >90% under age 65 to 80.8% at age 80 and 74.6% at age 90.
  • In probable AD dementia, plasma biomarkers, especially p-tau217, had PPVs above 95% for Aβ+ at all ages; the highest NPV for probable AD dementia was for p-tau217, reaching 60% by age 90.
  • In non-AD dementia syndromes, especially frontotemporal dementia, vascular dementia, and corticobasal syndrome, p-tau217 could rule out AD pathology with NPVs above 90% in nearly all circumstances; two exceptions were vascular dementia >90 years (NPV 89.4%) and corticobasal syndrome <65 years (NPV 88.2%).
  • Across cohorts and assays, p-tau217 had the highest PPVs and NPVs; GFAP performed next best but with lower specificity, and NfL had relatively lower PPV and NPV.

Methods

  • Cross-sectional diagnostic study of individuals from 11 cohort studies in Canada, France, South Korea, Spain, Sweden, and the United States; 6,896 participants total, mean age 69.7 years, 53.6% female.
  • Participants had standardized cognitive assessments, plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL), and reference standard AD biomarkers from PET, CSF, or neuropathology.
  • Biomarker abnormality was defined using z-scores ≥1.5 based on cognitively unimpaired controls without elevated amyloid-β pathology, and prevalence-adjusted PPVs/NPVs were calculated using Bayesian formulas with age-specific amyloid-β prevalence estimates from published meta-analyses; sensitivity analyses adjusted for APOE ε4 and alternative prevalence estimates.

Limitations

  • The paper states that its binary disease classification is a limitation, because biomarker accuracy is expected to be higher in later-stage disease.
  • It also states that the study is cross-sectional and not designed to predict future AD dementia.
  • It states that prevalence estimates came mainly from memory clinic and research settings, so PPV/NPV estimates should not be extrapolated to settings with substantially different prevalence.
  • Evident from the text: the main performance estimates depend on published prevalence assumptions rather than a single unified prospective clinical population, so generalizability to routine nonspecialist care may be limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s43587-024-00731-y

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PPVs and NPVs of plasma AD biomarkers in individuals with MCI. Age-associated PPV (left) and NPV (right) of five plasma biomarkers for amyloid PET positivity in MCI. The solid lines represent the point estimate, and error bars represent 95% CIs. Source data
Fig. 1 PPVs and NPVs of plasma AD biomarkers in individuals with MCI. Age-associated PPV (left) and NPV (right) of five plasma biomarkers for amyloid PET positivity in MCI. The solid lines represent the point estimate, and error bars represent 95% CIs. Source dataCC BY · PubMed Central
Fig. 2 PPVs and NPVs of plasma biomarkers of AD in individuals with probable AD dementia. Age-associated PPV (left) and NPV (right) of five plasma biomarkers for amyloid PET positivity in probable AD dementia. The solid lines represent the point estimate, and error bars represent 95% CIs. Source data
Fig. 2 PPVs and NPVs of plasma biomarkers of AD in individuals with probable AD dementia. Age-associated PPV (left) and NPV (right) of five plasma biomarkers for amyloid PET positivity in probable AD dementia. The solid lines represent the point estimate, and error bars represent 95% CIs. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

30 Valid · 2 Not valid · 4 Not checked · 41 Own results and interpretations

36 more claims · 10 with their cited sources checked

Create a free account to see all 77 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 14
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Citations

Cites

Show all 66 references

Research works printed but not linked: 1

  1. Campbell, M. J., Machin, D. & Walters, S. J. Medical Statistics: a Textbook for the Health Sciences (Wiley, 2021).

Cited by

See all 131

Metadata

Authors
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., Mielke, M. M., Hyung Hong, C., Roh, H. W., Contador, J., Puig Pijoan, A., Algeciras-Schimnich, A., Vemuri, P., Graff-Radford, J., Lowe, V. J., Karikari, T. K., Jonaitis, E., Brum, W., Tissot, C., Servaes, S., Rahmouni, N., Macedo, A. C., Stevenson, J., Fernandez-Arias, J., Wang, Y.-T., Woo, M. S., Friese, M. A., Jia, W. L., Dumurgier, J., Hourregue, C., Cognat, E., Ferreira, P. L., Vitali, P., Johnson, S., Pascoal, T. A., Gauthier, S., Lleó, A., Paquet, C., Petersen, R. C., Salmon, D., Mattsson-Carlgren, N., Palmqvist, S., Stomrud, E., Galasko, D., Son, S. J., Zetterberg, H., Fortea, J., Suárez-Calvet, M., Jack, C. R., Blennow, K., Hansson, O., & Rosa-Neto, P.
Affiliations
  • Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l’Île-de-Montréal (CA)
  • Lund University (SE)
  • University of Gothenburg (SE)
  • King's College London (GB)
  • University of Pittsburgh (US)
  • Universitat Autònoma de Barcelona (ES)
  • Inserm (FR)
  • Mayo Clinic (US)
  • Ajou University (KR)
  • University of Wisconsin–Madison (US)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Lawrence Berkeley National Laboratory (US)
  • University Medical Center Hamburg-Eppendorf (DE)
  • McGill University (CA)
  • University of California San Diego (US)
  • Wallenberg Centre for Molecular and Translational Medicine (SE)
Corresponding author
Therriault, Joseph
Venue
Nature Aging
Published
2024-11-12
Volume
4
Issue
11
Pages
1529-1537
ISSN
2662-8465 (ISSN-L)
OpenAlex
W4404252863
Cited by
131
References
66
Citations by year
2026: 70 · 2025: 58 · 2024: 3
FWCI
30.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Aging (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • AJOU Open Repository (Ajou University) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Alzheimer's Association (ADSF-21-831377-C, ADSF‐21‐831376‐C, #ADSF-21-831381-C, NIRP-12-259245, #NIRG‐12‐92090, 34874, 33397, SG-23-1061717, -21- 831377-C)
  • Familjen Erling-Perssons Stiftelse (860197)
  • Cure Alzheimer's Fund
  • McGill University (162303, MOP-11-51-31, RFN 152985, 159815)
  • Faculty of Medicine, McGill University
  • Fondation Brain Canada (2020-VICO-279314, 34874, 33397)
  • Stiftelsen för Gamla Tjänarinnor (FO2022‐0270, 860197)
  • Weston Brain Institute
  • EU Joint Programme – Neurodegenerative Disease Research (JPND 2021-00694)
  • Australian Government
  • National Institute for Health and Care Research
  • University College London (UKDRI‐1003)
  • European Commission (101,053,962, JPND2021‐00694, HORIZON2020, ALFGBG-71320, 860197)
  • Lunds Universitet
  • Hjärnfonden (FO2021-0293, #FO2022-0270, 1412/22)
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383)
  • Vetenskapsrådet (#101053962, 2022-01018, 2022-00775, ALFGBG‐71320, FO2021-0293, 2019-02397, AF-980907, 1412/22, 2017-00383)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028)
  • Skånes universitetssjukhus (2022-1259, 2020-O000028, 2022-Projekt0080)
  • UK Dementia Research Institute (UKDRI‐ 1003)
  • National Institutes of Health
  • Parkinsonfonden (1412/22)
  • HORIZON EUROPE Framework Programme (101053962, 860197)
  • Canadian Institutes of Health Research (#MOP-11-51-31, 201809, 152985, 159815, RFN 152,985, 162303, 92090)
  • Instituto de Salud Carlos III (PI19/00155)
  • National Institute on Aging (U01AG006786, R01AG054073, R01AG041851, R37AG011378, P30AG062429, R01AG058533, R01AG021155, R01AG027161, P30AG072980, R01AG083874, U19AG078109, P30AG072947)
  • National Institute of Biomedical Imaging and Bioengineering (P41EB015922)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, plasma biomarkers, amyloid-beta pathology, phosphorylated tau217, predictive value, mild cognitive impairment, dementia, anti-amyloid immunotherapy, confirmatory testing
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Probability, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability. https://app.cochat.ai/papers/10.1038/s43587-024-00731-y
The paper
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., Mielke, M. M., Hyung Hong, C., Roh, H. W., Contador, J., Puig Pijoan, A., Algeciras-Schimnich, A., Vemuri, P., Graff-Radford, J., Lowe, V. J., . . . Rosa-Neto, P. (2024). Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability. Nature Aging. https://doi.org/10.1038/s43587-024-00731-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.